TY - JOUR
T1 - Compressed nanofibrous oral tablets
T2 - An ingenious way for controlled release kinetics of Amphotericin-B loaded gelatin nanofibers
AU - Laha, Anindita
AU - Gaydhane, Mrunalini K.
AU - Sharma, Chandra S.
AU - Majumdar, Saptarshi
N1 - Funding Information:
Authors acknowledge Dr. Debaprasad Shee, IIT Hyderabad for providing us the facility to carry out FTIR and TGA analysis. We acknowledge Dr. Mudrika Khandelwal, IIT Hyderabad, for providing us the necessary amenities to perform antifungal testing. We also acknowledge Dr. Subha Narayan Rath and Mr. Akshay Bhatt, IIT Hyderabad, for helping us in performing MTT assay. The current research has been funded by DST Nano Mission project, India (Grant No. DST Ref No. - SR/NM/NS-1006/2016). DST INSPIRE Faculty, India grant (CSS) for electrospinning set up is also greatly acknowledged.
Funding Information:
The current research has been funded by DST Nano Mission project, India (Grant No. DST Ref No. - SR/NM/NS-1006/2016 ). DST INSPIRE Faculty, India grant (CSS) for electrospinning set up is also greatly acknowledged.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/7
Y1 - 2019/7
N2 - Amphotericin B (AmB) is one of the potent antimycotic drugs used to cure invasive fungal infections and Leishmaniasis. However, it's appalling collateral toxicity restricts its applicability for only parenteral administration with frequent dosing. Further, AmB is amphipathic and exhibits negligible absorption during oral administration due to its poor solubility. Current research unfolds the possibility to deliver AmB in a controlled way through oral route. First, homogeneous solution of gelatin-AmB was successfully electrospun into the nanofibers followed by crosslinking and compression to form compressed nanofibrous oral tablet (CNOT) containing 20 mg AmB in a 500 mg tablet. In-vitro biodegradation and thermal stability were investigated followed by studying the drug release kinetics. Antifungal activity was also examined up to seven days. AmB loaded CNOT showed zero order release profile with prominent antifungal activity up to seven days against Candida albicans. This study paves the way for a safe, yet effective oral administration of AmB while still maintaining the therapeutic efficacy for treating life-threatening fungal infections.
AB - Amphotericin B (AmB) is one of the potent antimycotic drugs used to cure invasive fungal infections and Leishmaniasis. However, it's appalling collateral toxicity restricts its applicability for only parenteral administration with frequent dosing. Further, AmB is amphipathic and exhibits negligible absorption during oral administration due to its poor solubility. Current research unfolds the possibility to deliver AmB in a controlled way through oral route. First, homogeneous solution of gelatin-AmB was successfully electrospun into the nanofibers followed by crosslinking and compression to form compressed nanofibrous oral tablet (CNOT) containing 20 mg AmB in a 500 mg tablet. In-vitro biodegradation and thermal stability were investigated followed by studying the drug release kinetics. Antifungal activity was also examined up to seven days. AmB loaded CNOT showed zero order release profile with prominent antifungal activity up to seven days against Candida albicans. This study paves the way for a safe, yet effective oral administration of AmB while still maintaining the therapeutic efficacy for treating life-threatening fungal infections.
UR - https://www.scopus.com/pages/publications/85069923722
UR - https://www.scopus.com/pages/publications/85069923722#tab=citedBy
U2 - 10.1016/j.nanoso.2019.100367
DO - 10.1016/j.nanoso.2019.100367
M3 - Article
AN - SCOPUS:85069923722
SN - 2352-507X
VL - 19
JO - Nano-Structures and Nano-Objects
JF - Nano-Structures and Nano-Objects
M1 - 100367
ER -